-0.0190  (-4.74%)
Volume (24h): 550.01K Day Range: 0.3650 - 0.4266
Market Cap: 35.05M 52W Range: 0.2500 - 3.08
Mar-11-20 12:00PM Acasti Pharma Awarded Notice of Allowance for Additional Composition of Matter and Method of Use Patents in the United States and MexicoGlobeNewswire
Mar-06-20 11:50AM Amarin Stock Looks Like a Heart-Healthy Buy on the DipInvestorPlace
Feb-28-20 10:00PM Acasti Receives NASDAQ Notification Regarding Minimum Bid RequirementsGlobeNewswire
07:48PM Look Anywhere but Acasti Pharma Stock for OpportunityInvestorPlace
Feb-28-20 03:07PM Confounding Decline Creates an Opportunity in Amarin StockInvestorPlace
Feb-14-20 04:41PM Risks Remain, but Amarin Stock Is a Buy at Today’s PricesInvestorPlace
01:00PM Acasti Pharma Provides Business Update for the Third Quarter of Fiscal 2020GlobeNewswire
Feb-13-20 02:00PM Acasti Pharma Schedules Third Quarter Fiscal 2020 and Business Update Conference CallGlobeNewswire
Feb-11-20 04:27PM 3 Beaten-Down Biotech Stocks With +50% Upside PotentialTipRanks
12:23PM The Daily Biotech Pulse: LogicBio Slapped With Clinical Hold, Agile Inks Debt Deal Ahead of Twirla Approval, Gilead Builds Stake In Sierra OncologyBenzinga
Feb-10-20 12:00PM Acasti Pharma Provides Update on TRILOGY 1 and TRILOGY 2 Phase 3 Trials of CaPreGlobeNewswire
Jan-17-20 04:07PM Does Acasti Stock Have a Future?InvestorPlace
11:30AM Why Amarin Stock Is Poised for a Healthy 2020InvestorPlace
Jan-14-20 02:46PM AstraZeneca to End Phase III Study on Fish Oil Heart DrugZacks
12:55PM The Daily Biotech Pulse: PhaseBio To Buy Hypertension Asset, Stemline Falls On Q4 Pre-Announcement, FDA Panel To Review Nektar's Opioid DrugBenzinga
Jan-13-20 09:22PM This Biotech Stock Is Flying High After Rival Heart Drugs StumbledInvestor's Business Daily
07:31PM Amarin's stock surges, as rival drugs from AstraZeneca, Acasti disappointMarketWatch
Jan-13-20 06:38PM Neptune Provides Updates on Non-Core InvestmentsCNW Group
04:07PM Amarin Stock Is Surging as Rival Makers of Fish-Oil Heart Drugs Fall
Jan-13-20 02:40PM This Biotech Stock Is Flying High After Rival Heart Drugs StumbledInvestor's Business Daily
11:00AM Acasti Pharma Reports Topline Results for TRILOGY 1 Phase 3 Trial of CaPreGlobeNewswire
Jan-10-20 03:59PM All Bets Are Off for Amarin StockInvestorPlace
Jan-09-20 01:56PM 3 Healthcare Stocks With Big Catalysts in JanuaryTipRanks
Dec-24-19 02:51PM Acasti Delays Data Readout For Drug To Treat Elevated TriglyceridesBenzinga
01:13PM Benzinga Pro's Top 5 Stocks To Watch For Tues., Dec. 24, 2019: TSLA, WCC, ACST, YMAB, ITCIBenzinga
Dec-24-19 12:24PM The Daily Biotech Pulse: NewLink Genetics Licenses Ovarian Cancer Dug, Correvio Awaits FDA VerdictBenzinga
01:31AM Acasti Pharma Provides Update on Timing of Topline Results for TRILOGY 1 Phase 3 Trial of CaPreGlobeNewswire
Dec-22-19 09:43PM Hedge Funds Have Never Been This Bullish On Acasti Pharma Inc. (ACST)Insider Monkey
Dec-20-19 09:41AM Amarin Stock is at Sky-High Levels Already Assumes All the Good NewsInvestorPlace
Nov-26-19 12:55PM Acasti Pharma Reports Last Patient Visit in TRILOGY 1 Phase 3 Trial of CaPre for the Treatment of Severe HypertriglyceridemiaGlobeNewswire
Nov-25-19 01:30PM Encode Ideas, L.P. Announces the Initiation of Research Coverage on Acasti Pharma, Inc.Newsfile
Nov-21-19 01:23PM Amarin's Shares Down on Underperform Rating by OppenheimerZacks
Nov-18-19 01:38PM Acasti Pharma Releases Preliminary New Animal Data, and Gains Insights Into CaPre’s Novel Mechanism of Action in DiabetesGlobeNewswire
Nov-13-19 12:55PM Acasti Pharma Provides Business Update for the Second Quarter of Fiscal 2020GlobeNewswire
Nov-07-19 01:30PM Acasti Pharma Announces Publication of CaPre Pharmacokinetics Study in a Leading Peer-Reviewed JournalGlobeNewswire
Nov-06-19 02:00PM Acasti Pharma Schedules Second Quarter Fiscal 2020 Conference CallGlobeNewswire
Nov-04-19 02:04PM Acasti Pharma Partners with Aker BioMarine to Supply Krill Oil for CaPre®GlobeNewswire
Oct-01-19 01:00PM Acasti Pharma to Present at the 2019 Cantor Fitzgerald Global Healthcare ConferenceGlobeNewswire
Sep-30-19 12:35PM Acasti Pharma Announces Additional Phase 3 Milestones Reached, and Remains on Track to Report Topline Results for TRILOGY 1 in December 2019 and TRILOGY 2 in January 2020GlobeNewswire
Sep-27-19 10:05AM Do Insiders Own Lots Of Shares In Acasti Pharma Inc. (CVE:ACST)?Simply Wall St.
Sep-09-19 12:30PM Acasti Pharma Receives Funding from the Government of Canada to Expand Production CapacityGlobeNewswire
Sep-04-19 01:00PM Acasti Pharma to Present at the 21st Annual Rodman & Renshaw Global Investment Conference in New York City on September 9thGlobeNewswire
Aug-28-19 08:05PM Acasti Pharma Announces the Election of Its Directors, Amendments to Its Stock Option and Equity Incentive Plans and Other Related Matters Approved at Its AGMGlobeNewswire
Aug-14-19 12:00PM Acasti Pharma Provides Business Update for the First Quarter of Fiscal 2020GlobeNewswire
Aug-09-19 12:00PM Acasti Pharma Co-Founder, Chief Operating and Scientific Officer to Participate on Lipid Panel at the 2019 BTIG Biotechnology ConferenceGlobeNewswire
Aug-07-19 12:00PM Acasti Pharma Schedules First Quarter Fiscal 2020 Conference CallGlobeNewswire
Jul-25-19 07:42PM Acasti Pharma Comments on Trading Activity and Reaffirms No Plans to Raise CapitalGlobeNewswire
Jul-05-19 12:35PM Bausch Gains 38.9% YTD on Product Launches & Debt ReductionZacks
Acasti Pharma Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of prescription drugs for the treatment of cardiovascular diseases. Its lead product candidate is CaPre, an omega-3 phospholipid therapeutic that is in Phase III clinical trial to treat patients with hypertriglyceridemia. The company was incorporated in 2002 and is headquartered in Laval, Canada.
Stocks in other countries: United Kingdom India Canada Australia
Market Cap
Volume (24h)